Abstract Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis. We studied 166 MBT specimens including 70 cases of lung cancer and 34 cases of breast cancer, and performed immunostaining for EGFR, COX-2, and O-6-methylguanine-DNA methyltransferase (MGMT), among others, which could be target molecules for therapeutic agents or enable prediction of drug efficacy. Loss of MGMT expression was observed in approximately 20-40 % of MBT derived from lung, breast, and gastrointestinal cancers, indicating the possibility of treatment of MBT patients with temozolomide. In addition, MBT expressed a variety of receptor tyrosine kinases, for example EGFR and HER2, and signal transduction molecules, for example phospho-mTOR and COX-2, irrespective of tumor origin, enabling individualized medication with molecule-targeting drugs. We also identified alteration of molecular expression profile in 4 MBT cases during recurrence. Our results not only reveal the molecular characteristics of MBT but also suggest the possibility of potent personalized medicine for MBT patients.
Introduction
The metastatic brain tumor (MBT) is the most frequently encountered intracranial tumor, although the reported incidence of MBT probably underestimates the true incidence because of underdiagnosis and inaccurate reporting [1] . The most common primary lesions of MBT in adults are the lung and the breast [1] ; more than 80 % of MBT are located in the cerebral hemisphere and approximately 15 % in the cerebellum [2] . If MBT is found in cancer patients after surgery and/or targeted chemotherapy against the primary tumor, the clinician usually offers the best supportive care. In fact, most chemotherapeutic agents are believed to be less effective than those for the primary lesion, mainly because of the blood-tumor barrier in the brain [1, 3] ; thus the prognosis for cancer patients with brain metastasis is extremely poor, even after the multimodal combination therapy of surgical resection, radiotherapy, and chemotherapy.
Recent progress in molecule-targeting therapy promises tumor type-specific and personalized treatment of cancer patients, especially those with lung and breast cancer. With regard to MBT treatment, dramatic responses to gefitinib and lapatinib of brain metastases from lung adenocarcinoma and breast cancer were recently reported [4] [5] [6] [7] [8] , and many clinical trials of molecule-targeting drugs against MBT are in progress [1] . To obtain the maximum therapeutic effect, a personalized pathological diagnosis based on the molecular expression profile beyond the types of primary organ is needed.
Extensive analysis of molecule-expression profiles in MBT are limited because of the difficulty of obtaining a large number of tumor samples from brain metastases. Several reports have revealed expression and alteration of several molecular markers, for example EGFR, COX-2, and VEGF-C, in MBT from lung cancer, although they failed to identify the clinical benefits of their studies [9] [10] [11] . In 234 cases of breast cancer, EGFR expression was identified in 18.4 %, although no detailed analysis of brain metastases was performed [12] . Here we performed immunohistochemical analysis to determine the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis which would be useful for offering personalized therapeutic strategies to patients with MBT.
Materials and methods

Ethical requirements
The study using human samples was performed with the approval of the Internal Review Board on Ethical Issues of Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Patients' demography and tumor specimens For histological examination we used 166 MBT specimens diagnosed between January 2003 and May 2012 in our faculty. The patients had been diagnosed with primary brain tumor or MBT without identification of primary lesions, and had undergone radical surgery. Formalin-fixed paraffin-embedded tissue blocks were prepared from surgical specimens, and sections were sliced and stained with hematoxylin and eosin (HE) for routine histopathological examination. Final diagnosis of MBT and identification of the primary tumor were performed by routine histological examination and immunohistochemical analysis. Characteristics of the patients are summarized in Table 1 . Ninetynine were male and 67 were female. Median age at surgery was 62.4 years (range 51-73).
Immunohistochemical analysis using tissue microarrays Tissue microarrays (TMA) were constructed by use of a Sakura Finetek (Tokyo, Japan) JF-4 tissue micro arrayer. Cylindrical cores 3.0 mm in diameter were taken from each tissue block. Immunohistochemical staining was performed as follows. The TMA sections were incubated with the indicated primary antibody and reacted with a dextran polymer reagent combined with secondary antibodies and peroxidase (Envision/HRP; Dako). The primary antibodies and conditions used for antigen retrieval in this analysis are summarized in Table 2 .
Each slide was evaluated independently by three pathologists (YK, HM, and HN). Immunostaining was evaluated for both the proportion and staining intensity of tumor cells in each case. The proportion was assessed according to the percentage of immunopositive cells as follows: 0, 0 %; ?1, less than 10 %; ?2, 10-50 %; or ?3, greater than 50 %. The staining intensity was evaluated as weak (?1), moderate (?2), or strong (?3). The membranous staining of PDGFRb, EGFR (wild type: WT), EGFR (L858R), EGFR (del), cKit, and cMET, or nuclear staining of MGMT were also restrictedly evaluated. The sum of the proportion score and the intensity score was evaluated as follows: MGMT and EGFR (WT), 3 ? 2 positive; others, 4 ? 2 positive.
Results
Characteristics of patients and primary lesions of MBT
A summary of the patients is shown in Table 1 and in Supplemental Fig. 1 . Median age of the patients was 62.4 years (range 51-73). Ninety-nine patients were men and 67 were women. The most frequent lesion was the lung in males (53.5 %) and the breast in females (50.1 %) followed by the gastrointestinal tract cancer (stomach, colon, and rectum); 13.3 % were primary-unknown at the time of initial pathological diagnosis. These results were in good agreement with a recent report from Europe [1] .
MGMT expression in MBT
Previously, MGMT expression in metastatic lung cancer and melanoma was evaluated [13, 14] , and we also established immunohistochemical validation of MGMT expression in surgical specimens [15] ; thus, we performed immunostaining to investigate MGMT expression in MBT. The results are given in Fig. 1 and Table 3 . MGMT was positive in 55 % of total MBT, and the positive ratio (75.0-79.4 %) for MBT of breast and gastrointestinal origin was much higher than for that of lung origin (53.3 %). For MBT derived from renal cancer, expression of MGMT was relatively low (28.6 %). Representative images of MGMT nuclear expression are given in Fig. 2 (S, T).
Expression profile of therapeutic target molecules in MBT
To propose potent personalized medicine for MBT patients with currently available molecule-targeting drugs, we evaluated the expression profile of the target molecules EGFR (WT), EGFR (L858R), EGFR (del 746-750), PDGFRb, HER2, cKit, cMET, phospho-mTOR, and COX-2 by immuohistochemistry. As shown in Fig. 2 , expression of PDGFRb, EGFR, HER2, cKit, and cMET was found in the cell membrane, and phospho-mTOR and COX-2 were located in the cytoplasm and partially in the cell membrane (phospho-mTOR). Positive results for each molecule according to primary tumor are summarized in Table 3 , Supplemental Fig. 2 , and Supplemental Fig. 3 . EGFR (WT) was highly expressed in MBT derived from breast (35.3 %), kidney (85.7 %), and lung (45.7 %). The mutant form of EGFR (L858R), indicative of favorable chemosensitivity to gefitinib [4] , was identified in 3 cases of MBT from breast cancer. HER2 was also expressed in metastatic gastric cancer (25.0 %) and lung cancer (2.9 %), but at levels lower than for breast cancer (52.9 %). cMET and phospho-mTOR were ubiquitously identified at high levels except in MBT from liver and kidney, and relatively high expression of cKit was observed in MBT of unknown origin (40.9 %). COX-2 expression was also identified in approximately 20 % of MBT from lung, breast, colorectal, and kidney cancer.
Alteration of molecular expression profile during recurrence
During this analysis we encountered 13 cases in which the patients underwent second radical surgery for recurrence of Table 3 for example loss or gain of EGFR expression, including wild type and mutant forms, cKit, and COX-2, were observed for 4 cases (Table 4 ; Fig. 3 ).
Discussion
Here we investigated the molecular expression profile of MBT and found a variety of molecular markers, for example EGFR, HER2, and MGMT, suggestive of potent personalized medication for MBT patients. Temozolomide (TMZ) is an oral alkylating agent used for treatment of malignant glioma and malignant melanoma [1] . The therapeutic mechanism of TMZ depends on its ability to alkylate/methylate DNA, usually at the N-7 or O-6 positions of guanine residues, resulting in death of the tumor cells [18] . However, if tumor cells express the enzyme O-6-methylguanine-DNA methyltransferase (MGMT), they are able to repair this type of DNA damage, thus reducing the therapeutic efficacy of temozolomide [19] . Although several retrospective and prospective phase II trials of TMZ for treatment of MBT have been reported, the therapeutic response was not dramatic [5] . This might be because the expression status of MGMT was not considered in these clinical trials. In fact, as shown in our analysis and in a previous report [14] , more than 50 % of MBT expressed MGMT; in particular, incidence of MGMT was high in MBT from breast and gastrointestinal cancer. Therefore, selection of MGMT-negative MBT patients by immunohistochemistry, irrespective of tumor origin, might yield a promising therapeutic response of MBT patients to TMZ. Promising personalized treatment by use of moleculetargeting drugs, for example gefitinib and lapatinib, is expected to be the new therapeutic strategy for MBT patients. In fact, many clinical trials with molecule-targeting drugs against MBT are in progress [1] . EGFRexpressing MBT might be sensitive to cetuximab treatment, because crossing of the blood-brain barrier and accumulation of cetuximab in brain metastases has been reported [20] . MBT with a mutated form of EGFR (L858R) could be a promising candidate for gefitinib treatment, although only 2 breast cancer cases out of a total of 166 cases were isolated in our analysis. The large number of MBT cases positive for cMET and/or phospho-mTOR might be possible targets for clinical trials with MET inhibitors and mTOR inhibitors [1] . Recent comparative genome-wide expression analysis in breast cancer patients with brain metastasis identified COX-2 as a mediator of cancer cell passage through the blood-brain barrier, and the efficacy of NSAID treatment of mice with brain metastasis from breast cancer has been proved [21, 22] . Therefore, overexpression of COX-2 in MBT suggests the anti-cancerous effect of COX-2 inhibitors, for example celecoxib, on MBT. These results encourage us to offer the challenging personalized molecule-targeting therapy; however, we must consider the discrepancy between the immunohistochemical expression of target molecules in tumor cells and the therapeutic efficacy of the molecule-targeting drugs.
Alteration of gene expression profile between primary and metastatic tumors has been reported in different types of cancer, for example lung, colorectal, and breast [9-11, 16, 17] . In this analysis, we isolated 13 cases of sequential recurrent brain metastasis including 4 cases in which the molecular expression profile was altered. For lung cancer cases, especially, alteration of EGFR expression was paradoxical; in one case loss of expression was observed but in the other case expression increased, with additional mutation of L858R. Loss of expression could result from therapeutic response to EGFR-targeting drugs, for example gefitinib, whereas increased expression and acquisition of additional mutation might be because two sequential MBT were derived from different clones of tumor cells in the same primary lung cancer. Detailed analysis of clinical courses and multiple gene expression analysis between the primary and metastatic tumors will reveal interesting phenomena such as those described above. In addition, these results inform us that re-evaluation of molecular expression profile by repeat brain biopsy might be required to achieve promising personalized medicine for MBT patients.
In conclusion, we investigated, by immunohistochemistry, the molecular expression profile of MBT which could reveal target molecules for therapeutic agents or for prediction of drug efficacy. Our results could be a pathological basis for personalized diagnosis which could enable personalized therapy for patients with MBT.
